Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Stargardt Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Stargardt Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 11 Stargardt Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (2 studies); the largest phase groups are Phase 1 / Phase 2: 2, Phase 1: 2.

Research is led by Ascidian Therapeutics, Inc (2), Ray Therapeutics, Inc. (2), Science Corporation (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is PRIMA Products (device, 1 trial), followed by Prescreening Assessments, AAVB-039.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Track Stargardt Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07266584

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but...

Sponsor: Science CorporationEnrolling: 51 location
RECRUITINGNCT06445322

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01...

Sponsor: Ascidian Therapeutics, IncEnrolling: 508 locations
RECRUITINGPhase 1 / Phase 2NCT07161544

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a...

Sponsor: AAVantgarde Bio SrlEnrolling: 758 locations
RECRUITINGPhase 1NCT07417566

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

This study adopts a randomized, double-blind, parallel placebo-controlled dose-escalation design, consisting of two parts: Part 1 includes a single ascending dose (SAD) study plus...

Sponsor: Heronova PharmaceuticalsEnrolling: 761 location
RECRUITINGNCT02435940

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by...

Sponsor: Foundation Fighting BlindnessEnrolling: 200001 location
RECRUITINGPhase 1 / Phase 2NCT06467344

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01...

Sponsor: Ascidian Therapeutics, IncEnrolling: 1510 locations
RECRUITINGNCT03011541

Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Sponsor: MD Stem CellsEnrolling: 5004 locations
RECRUITINGNCT06805474

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when...

Sponsor: Nanoscope Therapeutics Inc.Enrolling: 301 location
RECRUITINGNCT07502664

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited...

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...

Sponsor: Ray Therapeutics, Inc.Enrolling: 251 location
RECRUITINGPhase 1NCT06319872

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and...

Sponsor: University of RochesterEnrolling: 151 location
RECRUITINGNCT06375239

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal...

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...

Sponsor: Ray Therapeutics, Inc.Enrolling: 1201 location

Frequently Asked Questions

There are currently 11 clinical trials for Stargardt Disease, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Stargardt Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Stargardt Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.